Close Menu

NEW YORK — Interpace Biosciences said on Monday that it has signed an agreement to sell $20 million in Series B preferred stock and that it is planning a one-for-10 reverse stock split.

According to the Parsippany, New Jersey-based company, 1315 Capital will purchase $19 million worth of the preferred stock, with the remaining $1 million being sold to existing investor Ampersand Capital Partners. The preferred stock is convertible into common stock at a conversion price of $.60 per share prior to the planned reverse stock split.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.